Last reviewed · How we verify
Placebo ELLIPTA inhaler
The Placebo ELLIPTA inhaler delivers no active pharmaceutical ingredient, serving as an inert control device in clinical trials.
The Placebo ELLIPTA inhaler is a device used in clinical trials by GlaxoSmithKline to serve as a control in studies evaluating the efficacy and safety of active drugs. It does not contain any active pharmaceutical ingredients and is designed to mimic the appearance and feel of the actual ELLIPTA inhaler. Since it is a placebo, it has no therapeutic effect and is not intended for use outside of clinical trials. The device is important for maintaining the integrity of blinded studies, ensuring that participants and researchers cannot distinguish between the placebo and the active treatment. No FDA label exists for this product, as it is not marketed for general use.
At a glance
| Generic name | Placebo ELLIPTA inhaler |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
This is a placebo device designed to match the physical appearance, handling, and user experience of the active ELLIPTA inhaler without containing any therapeutic agent. It is used in randomized controlled trials to provide a blinded comparator arm, allowing researchers to isolate the true pharmacological effects of active medications from placebo response and device-related effects.
Approved indications
- Clinical trial control comparator (not a therapeutic indication)
Common side effects
Key clinical trials
- Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators (PHASE4)
- Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year (PHASE4)
- A Comparison of Critical Errors, Overall Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers (DPIs) in Adult Participants With Asthma (PHASE4)
- A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation (PHASE2)
- A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
- Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery (PHASE3)
- An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo ELLIPTA inhaler CI brief — competitive landscape report
- Placebo ELLIPTA inhaler updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI